DK2857039T3 - Terapeutisk middel eller profylaktisk middel mod demens - Google Patents
Terapeutisk middel eller profylaktisk middel mod demens Download PDFInfo
- Publication number
- DK2857039T3 DK2857039T3 DK13797290.7T DK13797290T DK2857039T3 DK 2857039 T3 DK2857039 T3 DK 2857039T3 DK 13797290 T DK13797290 T DK 13797290T DK 2857039 T3 DK2857039 T3 DK 2857039T3
- Authority
- DK
- Denmark
- Prior art keywords
- demens
- agent
- prophylactic
- therapeutic agent
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2857039T3 true DK2857039T3 (da) | 2019-12-16 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13797290.7T DK2857039T3 (da) | 2012-05-31 | 2013-05-30 | Terapeutisk middel eller profylaktisk middel mod demens |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102208283B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2763361T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG10201805410XA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI700296B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012162179A1 (en) * | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| TWI700296B (zh) * | 2012-05-31 | 2020-08-01 | 公立大學法人大阪市立大學 | 失智症治療劑或預防劑 |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ |
| CA3053379A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| CA3056573A1 (en) | 2017-05-30 | 2018-12-06 | Teijin Pharma Limited | Anti-igf-i receptor antibody |
| GEAP202215303A (en) | 2017-10-02 | 2022-04-11 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| JP7504026B2 (ja) | 2018-04-06 | 2024-06-21 | 帝人ファーマ株式会社 | Ｓｐｎｓ２中和抗体 |
| EP3819378A4 (en) | 2018-07-04 | 2022-09-14 | Aichi Medical University | OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JP7718270B2 (ja) | 2019-09-30 | 2025-08-05 | ニプロ株式会社 | 血液試料を検体とするタウタンパク質検出方法 |
| JP2023518281A (ja) * | 2020-03-19 | 2023-04-28 | ヴァスキュラー バイオサイエンスィズ | コロナウイルス生存率改善のためのｃａｒペプチド |
| CN116723856A (zh) * | 2020-06-25 | 2023-09-08 | 默沙东有限责任公司 | 靶向丝氨酸413处磷酸化的tau的高亲和力抗体 |
| CA3203800A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026102093A1 (en) | 2024-11-07 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| WO1997034145A1 (fr) * | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| JP2009539406A (ja) * | 2006-06-16 | 2009-11-19 | エンビボ ファーマシューティカルズ インコーポレイテッド | タウおよびアミロイド前駆体断片を発現する遺伝子組換えハエ |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| TWI700296B (zh) * | 2012-05-31 | 2020-08-01 | 公立大學法人大阪市立大學 | 失智症治療劑或預防劑 |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2013
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277912A (en) | Targeted therapeutics | |
| EP2858708A4 (en) | INFLATABLE MEDICAL DEVICES | |
| PL2863961T3 (pl) | Urządzenia hemostatyczne | |
| EP2941539A4 (en) | PROPELLER | |
| EP2914098A4 (en) | Emergency leash | |
| DK2891492T3 (da) | Endoparasit kontrol middel | |
| EP2916905A4 (en) | MEDICAL CONNECTOR | |
| EP2842540A4 (en) | MEDICAL CONNECTOR | |
| EP3804591C0 (en) | SKIN CLEANSING DEVICE | |
| BR302012006715S1 (pt) | Configuração aplicada em lâmina | |
| HUE068959T2 (hu) | Dekódolási eljárás | |
| EP2832398A4 (en) | MEDICAL SHUTTER | |
| DK2861573T3 (da) | Oxathiazin-derivater som antibakterielle og anticancer-stoffer | |
| EP2873441A4 (en) | EXTINGUISHERS | |
| DK3033242T3 (da) | Cykloidalt hjuldrev | |
| EP2884064A4 (en) | MUFFLER | |
| EP2860233A4 (en) | PUNCTURE CLOSURE MEANS | |
| BR302012003683S1 (pt) | Configuração aplicada em poltrona | |
| BR302012004780S1 (pt) | Lâmina | |
| FI20125510L (fi) | Laitteisto | |
| EP2839273A4 (en) | MULTILAYER GEL | |
| LT2812013T (lt) | Kompozicija, skirta džs gydymui | |
| EP2931176A4 (en) | Medical sling | |
| EP2789306A4 (en) | TREATMENT SYSTEM | |
| DK2914574T3 (da) | Ny fremgangsmåde |